# A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.

> **NCT00040677** · PHASE2 · COMPLETED · sponsor: **Icagen** · enrollment: 90 (actual)

## Conditions studied

- Sickle Cell Disease
- Sickle Cell Anemia

## Interventions

- **DRUG:** Low Dose ICA-17043
- **DRUG:** High dose ICA-17043
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00040677
- **Lead sponsor:** Icagen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-02
- **Primary completion:** 2003-11
- **Final completion:** 2004-01
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2011-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00040677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00040677, "A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00040677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*